Von Hippel-Lindau protein-mediated repression of tumor necrosis factor alpha translation revealed through use of cDNA arrays

Molecular and Cellular Biology

Volumn 23, Issue 7, 2003, Pages 2316-2328

  Galbán, Stefanie ^a   Fan, Jinshui ^a   Martindale, Jennifer L ^a   Cheadle, Chris ^a   Hoffman, Bryan ^b   Woods, Michael P ^b   Temeles, Gretchen ^b   Brieger, Jürgen ^c   Decker, Jochen ^d   Gorospel, Myriam ^a,e  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b Message Pharmaceuticals Inc   (United States)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d Bioscientia Center for Human Genetics   (Germany)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

3' UNTRANSLATED REGION; ARTICLE; CONTROLLED STUDY; CYTOSOL; DNA HYBRIDIZATION; DNA MICROARRAY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; NUCLEOTIDE SEQUENCE; POLYSOME; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN SYNTHESIS; REPORTER GENE; RNA TRANSLATION;

3' UNTRANSLATED REGIONS; BLOTTING, NORTHERN; CARCINOMA, RENAL CELL; CYTOSOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; GENES, TUMOR SUPPRESSOR; HUMANS; LIGASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYRIBOSOMES; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0037377756     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.23.7.2316-2328.2003     Document Type: Article

References (60)

1. Ballwill, F. 2002. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 13:135-141.
2. Balkwill, F., and A. Mantovani. 2001. Inflammation and cancer: back to Virchow? Lancet 357:539-545.
3. Bindra, R. S., J. R. Vasselli, R. Stearman, W. M. Linehan, and R. D. Klausner. 2002. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res. 62:3014-3019.
4. Caldwell, M. C., C. Hough, S. Fürer, W. M. Linehan, P. J. Morin, and M. Gorospe. 2002. Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNF-α cytotoxicity. Oncogene 21:929-936.
5. Cheadle, C., M. P. Vawter, W. J. Freed, and K. G. Becker. Analysis of microarray data using Z score transformation. J. Mol. Diagn., in press.
6. Corless, C. L., A. Kibel, O. Iliopoulos, and W. G. Kaelin. 1997. Immunostaining of the von Hippel-Lindau gene product (pVHL) in normal and neoplastic human tissues. Hum. Pathol. 28:459-464.
7. Duan, D. R., A. Pause, W. Burgess, T. Aso, D. Y. T. Chen, K. P. Garrett, R. C. Conaway, J. W. Conaway, W. M. Linehan, and R. D. Klausner. 1995. Inhibition of transcriptional elongation by the VHL tumor suppressor protein. Science 269:1402-1406.
8. Elson, D. A., G. Thurston, L. E. Huang, D. G. Ginzinger, D. M. McDonald, R. S. Johnson, and J. M. Arbeit. 2001. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes Dev. 15:2520-2532.
9. Fan, J., X. Yang, W. Wang, W. H. Wood III, K. G. Becker, and M. Gorospe. 2002. Global analysis of stress-regulated mRNA turnover by using cDNA arrays. Proc. Natl. Acad. Sci. USA 99:10611-10616.
10. Forsythe, J. A., B. H. Jiang, N. V. Iyer, F. Agani, S. W. Leung, R. D. Koos, and G. L. Semenza. 1996. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16:4604-4613.
11. Gnarra, J. R., S. Zhou, M. J. Merrill, J. R. Wagner, A. Krumm, E. Papavassiliou, E. H. Oldfield, R. D. Klausner, and W. M. Linehan. 1996. Posttranscriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl. Acad. Sci. USA 93:10589-10594.
12. 1 cyclin-dependent kinase activity during growth arrest of human breast carcinoma cells by prostaglandin A2. Mol. Cell. Biol. 16:762-770.
13. Gorospe, M., J. M. Egan, B. Zbar, M. Lerman, L. Geil, I. Kuzmin, and N. J. Holbrook. 1999. Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells. Mol. Cell. Biol. 19:1289-1300.
14. Gorospe, M., and N. J. Holbrook. 1996. Role of p21 in prostaglandin A2-mediated cellular arrest and death. Cancer Res. 56:475-479.
15. Gueydan, C., L. Droogmans, P. Chalon, G. Huez, D. Caput, and V. Kruys. 1999. Identification of TIAR as a protein binding to the translational regulatory AU-rich element of tumor necrosis factor-α mRNA. J. Biol. Chem. 274:2322-2326.
16. Hansen, W. J., M. Ohh, J. Moslehi, K. Kondo, W. G. Kaelin, and W. J. Welch. 2002. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Mol. Cell. Biol. 22:1947-1960.
17. Iliopoulos, O., A. Kibel, S. Gray, and W. G. Kaelin, Jr. 1995. Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1:822-826.
18. Iliopoulos, O., A. P. Levy, C. Jiang, W. C. Kaelin, Jr., and M. A. Goldberg. 1996. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA 93:10595-10599.
19. Ivan, M., and W. G. Kaelin. 2001. The von Hippel-Lindau tumor suppressor protein. Curr. Opin. Genet. Dev. 11:27-34.
20. Iyer, S., D. Kontoyiannis, D. Chevrier, J. Woo, N. Mori, M. Coruejo, G. Kollias, and R. Buelow. 2000. Inhibition of tumor necrosis factor mRNA translation by a rationally designed immunomodulatory peptide. J. Biol. Chem. 275:17051-17057.
21. Johannes, G., M. S. Carter, M. B. Eisen, P. O. Brown, and P. Sarnow. 1999. Identification of eukaryotic mRNAs that are translated at reduced cap binding complex cIF4F concentrations using a cDNA microarray. Proc. Natl. Acad. Sci. USA 96:13118-13123.
22. Kaelin, W. G. 2002. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2:673-682.
23. Kedersha, N. L., M. Gupta, W. Li, I. Miller, and P. Anderson. 1999. RNA-binding proteins TIA-1 and TIAR link the phosphorylation of eIF-2α to the assembly of mammalian stress granules. J. Cell Biol. 147:1431-1442.
24. Komori, A., J. Yatsunami, M. Suganuma, S. Okabe, S. Abe, A. Sakai, K. Sasaki, and H. Fujiki. 1993. Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation. Cancer Res. 53:1982-1985.
25. Koochekpour, S., M. Jeffers, P. H. Wang, C. Gong, G. A. Taylor, L. M. Roessler, R. Stearman, J. R. Vasselli, W. G. Stetler-Stevenson, W. G. Kaelin, Jr., W. M. Linehan, R. D. Klausner, J. R. Gnarra, and G. F. Vande Woude. 1999. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol. Cell. Biol. 19:5902-5912.
26. Kroll, S. L., W. R. Paulding, P. O. Schnell, M. C. Barton, J. W. Conaway, R. C. Conaway, and M. F. Czyzyk-Krzeska. 1999. von Hippel-Lindau protein induces hypoxia-regulated arrest of tyrosine hydroxylase transcript elongation in pheochromocytoma cells. J. Biol. Chem. 274:30109-30114.
27. Kruys, V., and G. Huez. 1994. Translational control of cytokine expression by 3′ UA-rich sequences. Biochimie 76:862-866.
28. Latif, F., K. Tory, J. Gnarra, M. Yao, F. M. Duh, M. L. Orcutt, T. Stackhouse, I. Kuzmin, W. Modi, L Geil, et al. 1993. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317-1320.
29. Lieberman, A. P., P. M. Pitha, and M. L., Shin. 1990. Protein kinase regulates tumor necrosis factor mRNA stability in virus-stimulated astrocytes. J. Exp. Med. 172:989-992.
30. 2 is mediated by enhanced cyclin D1 mRNA turnover. Mol. Cell. Biol. 20:7903-7913.
31. Locksley, R. M., N. Killeen, and M. J. Lenardo. 2001. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104:487-501.
32. Los, M., G. H. Jansen, W. G. Kaelin, C. J. Lips, G. H. Blijham, and E. E. Voest. 1996. Expression pattern of the von Hippel-Lindau protein in human tissues. Lab. Investig. 75:231-238.
33. Mahtani, K. R., M. Brook, J. L. Dean, G. Sully, J. Saklatvala, and A. R. Clark. 2001. Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability. Mol. Cell. Biol. 21:6461-6469.
34. Maxwell, P. H., M. S. Wiesener, G.-W. Chang, S. C. Clifford, E. C. Vaux, M. E. Cockman, C. C. Wykoff, C. W. Pugh, E. R. Maher, and P. J. Ratcliffe. 1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275.
35. Mukhopadhyay, D., B. Knebelmann, H. T. Cohen, S. Ananth, and V. P. Sukhatme. 1997. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol. Cell. Biol. 17:5629-5639.
36. Nakajima, K., M. Sasaki, D. Nojima, B. R. Oh, N. Ishii, K. Miura, and R. Dahiya. 2001. Tumor necrosis factor-α gene mutations and genotype changes in renal cell carcinoma. J. Urol. 165:612-615.
37. Ohh, M., C. W. Park, M. Ivan, M. A. Hoffman, L. E. Huang, V. Chau, and W. G. Kaelin. 2000. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. J. Biol. Chem. 275:25733-25741.
38. Ohh, M., R. L. Yauch, K. M. Lonergan, J. M. Whaley, A. O. Stemmer-Rachamimov, D. N. Louis, B. J. Gavin, N. Kley, W. G. Kaelin, Jr., and O. Iliopoulos. 1998. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell 1:959-968.
39. Piecyk, M., S. Wax, A. R. Beck, N. Kedersha, M. Gupta, B. Maritim, S. Chen, C. Gueydan, V. Kruys, M. Streuli, and P. Anderson. 2000. TIA-1 is a translational silencer that selectively regulates the expression of TNF-α. EMBO J. 19:4154-4163.
40. Pioli, P. A., and W. F. Rigby. 2001. The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein A2 and regulates its expression. J. Biol. Chem. 276:40346-40352.
41. Prichett, W., A. Hand, J. Sheilds, and D. Dunnington. 1995. Mechanism of action of bicyclic imidazoles defines a translational regulatory pathway for tumor necrosis factor-α. J. Inflamm. 45:97-105.
42. Richardson, P., T. Hideshima, and K. Anderson. 2002. Thalidomide: emerging role in cancer medicine. Annu. Rev. Med. 53:629-657.
43. Schoenfeld, A., E. Davidowitz, and R. A. Burk. 1998. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc. Natl. Acad. Sci. USA 95:8817-8822.
44. Selby, P., S. Hobbs, C. Viner, E. Jackson, A. Jones, D. Newell, A. H. Calvert, T. McElwain, K. Fearon, J. Humphreys, et al. 1987. Tumour necrosis factor in man: clinical and biological observations. Br. J. Cancer 56:803-808.
45. Semenza, G. L., and G. L. Wang. 1992. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoienin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol. 12:5447-5454.
46. Stebbing, J., C. Benson, T. Eisen, L. Pyle, K. Smalley, H. Bridle, I. Mak, F. Sapunar, R. Ahern, and M. E. Gore. 2001. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br. J. Cancer 85:953-958.
47. Tisdale, M. J. 1997. Biology of cachexia. J. Natl. Cancer Inst. 89:1763-1773.
48. Tsuchiya, H., T. Iseda, and O. Hino. 1996. Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product. Cancer Res. 56:2881-2885.
49. Vawter, M. P., T. Barrett, C. Cheadle, B. P. Sokolov, W. H. Wood, D. Donovan, M. Webster, W. J. Freed, and K. G. Becker. 2001. Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Res. Bull. 55:641-650.
50. Wang, W., S. Lin, C. M. Caldwell, H. Furneaux, and M. Gorospe. 2000 HuR regulates cyclin A and cyclin B1 mRNA stability during the cell division cycle. EMBO. J. 19:2340-2350.
51. Wang, W., H. Furneaux, H. Cheng, M. C. Caldwell, D. Hutter, Y. Liu, N. J. Holbrook, and M. Gorospe. 2000. HuR regulates p21 mRNA stabilization by UV light. Mol. Cell. Biol. 20:760-769.
52. Willeaume, V., V. Kruys, T. Mijatovic, and G. Huez. 1995. Tumor necrosis factor-α production induced by viruses and by lipopolysaccharides in macrophages: similarities and differences. J. Inflamm. 46:1-12.
53. Wizigmann-Voos, S., G. Breier, W. Risau, and K. Plate. 1995. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res. 55:1358-1364.
54. Wu, S., C. M. Boyer, R. S. Whitaker, A. Berchuck, J. R. Wiener, J. B. Weinberg, and R. C. Bast, Jr. 1993. Tumor necrosis factor-α as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor-α expression. Cancer Res. 53:1939-1944.
55. Wykoff, C., C. Pugh, P. Maxwell, A. Harris, and P. Ratcliffe. 2000. Identification of novel hypoxia-dependent and -independent target genes of the von Hippel-Lindau (VHL) tumor suppressor by mRNA differential expression profiling. Oncogene 19:6297-6305.
56. Yoneda, T., R. M. Lyall, M. M. Alsina, P. E. Persons, A. P. Spada, A. Levitzki, A. Zilberstein, and G. R. Mundy. 1991. The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice. Cancer Res. 51:4430-4435.
57. Yoshida, N., S. Ikemoto, K. Narita, K. Sugimura, S. Wada, R. Yasumoto, T. Kishimoto, and T. Nakatani. 2002. Interleukin-6, tumour necrosis factor-α and interleukin-1β in patients with renal cell carcinoma. Br. J. Cancer 86:1396-1400.
58. Zatyka, M., N. F. da Silva, S. C. Clifford, M. R. Morris, M. S. Wiesener, K. U. Eckardt, R. S. Houlston, F. M. Richards, F. Latif, and E. R. Maher. 2002. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res. 62:3803-3811.
59. Zhou, M. I., H. Wang, J. J. Ross, I. Kuzmin, C. Xu, and H. T. Cohen. 2002. The von Hippel-Lindau (VHL) tumor suppressor stabilizes novel PHD protein Jade-1. J. Biol. Chem. 277:39887-39898.
60. Zong, Q., M. Schummer, L. Hood, and D. R. Morris. 1999. Messenger RNA translation state: the second dimension of high-throughput expression screening. Proc. Natl. Acad. Sci. USA 96:10632-10636.